{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-251698","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.692049+00:00","generated_at":"2026-05-30T04:43:21.987994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma Q3 portfolio receipts up 15% to $735M; raises FY guidance to $2.75-2.8B","bullets":["Royalty Receipts grew 15% to $732M; Portfolio Receipts $735M, driven by Trelegy, Evrysdi, cystic fibrosis franchise.","Full-year 2024 Portfolio Receipts guidance raised to $2.75B-$2.8B (from $2.7B-$2.775B); Royalty Receipts growth 11-13%.","Capital Deployment of ~$1.2B in Q3; acquired synthetic royalties on Niktimvo ($350M) and Yorvipath ($150M).","Net cash from operations $704M; repurchased ~3M shares for $95M during Q3; cash and equivalents $950M.","FDA approvals for Cobenfy (schizophrenia), Tremfya (ulcerative colitis), Voranigo (glioma) benefit royalty portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-251698","json":"https://secwatch.observer/filing/0001193125-24-251698.json","markdown":"https://secwatch.observer/filing/0001193125-24-251698.md","text":"https://secwatch.observer/filing/0001193125-24-251698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524251698/0001193125-24-251698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524251698/d904706d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:43:21.987994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}